Good morning. Futures pointing higher after a torrent of AI news. MU +8% getting close to $1T on a $250B US investment acceleration through 2035 — memory-as-custom-silicon re-rating in full effect. META target 14GW compute by 2027, up from 7GW, and Zuck breaks Twitter silence to hype Muse Spark 1.1 — kills the “excess compute” narrative cold. OpenAI drops GPT-5.6 with persistent agentic workloads: internal agent token usage up 22x in six months. Jevons paradox? More like Jevons freight train. CRM down 4% on KeyBanc downgrade citing Agentforce lack of momentum — enterprise AI adoption is not automatic. IBM slips 3% as Starbucks builds in-house AI to replace legacy software. Chinese AI models gaining share per Apollo data. SK Hynix’s $26.5B US IPO 7x oversubscribed — HBM monopoly premium getting priced. Three themes frame the day: (1) Agentic workloads structurally expand inference demand — positive for NVDA, AMD, MU, LITE, CIEN. (2) Memory is the new custom silicon — MU and SKHY lead, with TSM, AMAT, LRCX as picks-and-shovels. (3) Enterprise AI has a long tail — CRM, IBM signal incumbents aren’t guaranteed winners; the real action is at the infrastructure layer. We’ll hit up MU and META first, then get to semis and networking.
Veridict: The Superior deal is the right move at the right price. MTZ just bought itself a dedicated data center electrical platform for 6.9x EBITDA, and the Street is rewarding it with target bumps across the board. The 8% pullback last week? Noise. This is a compounder.
$1.65B for Superior Group ($1.175B cash + $475M stock). 90% of Superior's revenue is data center-facing. Implied multiple: 6.9x 2026E EBITDA, with revenue guidance suggesting 40%+ growth in 2027 and low-teens EBITDA margins. Management stays. Folds into Power Delivery segment. Closes mid-to-late July.
13 firms lifted PTs to a $455-$545 range from prior mid-$400s cluster. Stifel held at $455 (Buy). Cantor at $545 (Overweight). Mizuho went to $502. KeyBanc to $500.
The collective thesis: this is exactly what MTZ telegraphed on Analyst Day — use M&A to build a scaled, self-performing electrical platform for the AI power demand cycle. No one is questioning the price. They’re asking what’s next.
Bull: Generational infrastructure cycle — AI data center load, grid hardening, Permian takeaway, fiber backhaul — and now MTZ owns the electrical contractor that plugs the servers in. Superior gives them a repeatable vertical in the fastest-growing end market. At 6.9x with 40% revenue growth baked in, the earnout is free optionality.
Bear: Integration risk is real. MasTec hasn't run a $1.65B electrical shop before. The stock is up 126% in a year — any execution slip and the multiple compresses. Also, 90% data center concentration in a single acquired company means if the AI buildout pauses, Superior becomes a millstone.
Cantor Fitzgerald: "The acquisition is strategically consistent and financially accretive, directly extending the framework MasTec outlined on Analyst Day."
Stock at $382.90 — that’s 13.5x forward EBITDA assuming $28B market cap and ~$2B+ EBITDA in 2027. Not cheap, but not insane for a company with 23% top-line growth and a new data center division. The 8% dip last week is a gift if you believe the cycle lasts more than 18 months.
Positioning: Own it. The long-duration structural tailwinds (electrification, AI, grid) are still early. MTZ is the best way to play the build-out without picking subsectors. Risk/reward leans bullish into earnings.
Verdict: Buy-side consensus is tightening around a massive WFE super-cycle. Two shops just pushed PTs to $400 — and that's actually the conservative end of the range now (Cantor at $500 is the outlier but not crazy). The story is pure rate-of-change: WFE estimates are being ripped higher for 2027-29 as AI-driven logic, memory, and HBM capex compound. LRCX is a leveraged play on that ramp.
Bull case: This isn't a normal cyclical upswing. AI inference and training are structurally increasing silicon content per node. HBM capex acceleration into 2027-28 coupled with a global memory shortage means equipment orders stay elevated for years. LRCX has deposition and etch exposure that benefits disproportionately from leading-edge DRAM and NAND. The $250B WFE scenario is becoming the base case, not the bull case.
Bear case: Stock is already up 236% in a year and trades at 63x P/E on trailing earnings. That's pricing in perfection — any hiccup in WFE trajectory (capex pause, trade war escalation, HBM oversupply) sends it down hard. The $400B WFE scenario requires a major NAND turnaround, which is not guaranteed. Risk/reward is asymmetric at this valuation.
"Memory sector fab return on investment stands at more than three times better versus prior cycles, with demand secured through take-or-pay agreements." > — TD Cowen
That's the line that matters. The take-or-pay construct fundamentally changes the equipment order cycle — it's no longer a spot market. LRCX gets paid even if utilization dips. That's why PTs are going up.
THE TAKE: FIX IS THE CLEANEST WAY TO PLAY THE DATA CENTER BUILD-OUT IN MECHANICAL/ELECTRICAL CONTRACTING. TWO BUYS THIS WEEK (UBS, GOLDMAN) WITH PTs CLUSTERED AT $2,125-2,159. STOCK AT $1,799 – STILL ROOM BUT RISK OF FOMO PULLBACK ON NORMAL SEASONAL BOOK-TO-BILL.
Goldman started coverage with Buy, $2,159 PT. Analyst Adam Bubes makes the case succinctly: FIX is a leading M&E contractor with 56% OF SALES FROM DATA CENTERS & SEMICONDUCTORS. He models 23% organic revenue CAGR through 2028, and says data center projects carry "meaningfully higher margins" – hence margin expansion is baked in. EBITDA estimates 9% above consensus for 2026-27.
UBS reiterated Buy with $2,125 PT after management meetings. They see continued robust pricing conditions and FIX’s scale helping it lock in large projects while using better wages to grow labor force. Expects Q2 upside to Street, but flags BOOK-TO-BILL AT 0.9-1.0X (NORMAL SEASONALITY) could disappoint if investors were hoping for a repeat of the last year's blowout prints. That's the execution risk.
Bull case: Multi-year hyperscaler buildout is non-discretionary spending. FIX's Texas overweight (Goldman's note) positions it for the fastest-growing data center market. Labor advantage (better wages = more workers) means it can take share. Margins structurally higher as mix shifts to data center.
Bear case: Valuation is already pricing in perfection – stock up 216% in a year. Normal book-to-bill is a near-term speed bump. If hyperscaler capex even modestly normalizes, multiple compression hits hard. And the stock's market cap ($59B) is now large enough that growth rates will decelerate organically.
From Goldman's initiation (emphasis added):
"The company is a leading mechanical and electrical contractor with significant leverage to the AI infrastructure build-out. Data centers and semiconductors represent 56% of sales... Our work suggests data center projects carry meaningfully higher margins."
That's the core thesis. FIX is an execution story in a structural tailwind. The risk is that everyone already knows it.
THE PRE-ANNOUNCE IS GOOD. THE RISK IS PULL-FORWARD. DOCN popped 365% in the last year — and now the bull case is fully baked into the stock at $138. Two analyst notes hit this morning and they tell the same story from opposite sides of the conviction spectrum.
Cantor is doubling down: Overweight, $177 PT. They see a THREE-PRONGED ACCELERATION — revenue growth (29% vs 14% a year ago), contracted backlog (RPO >$800M, 10x YoY), and margins (EBITDA at or above high end of guide). The thesis is simple: AI-native customers are signing nine-figure annual commitments for inference and cloud, and DOCN is adding 20MW in late 2027/early 2028 to take total capacity to ~155MW. Management says current momentum positively impacts the 2026 exit growth rate, previously guided to approach 30%.
UBS cuts PT to $155 from $175, stays Neutral. They’re not bearish — they just think the easy money’s been made. The $24M sequential revenue bump in Q2 implies the Richmond 6MW is NEAR FULLY UTILIZED. Average backlog duration >3 years is longer than expected — that’s good for visibility but also means current customers are locking up capacity that could go to higher-priority deals later.
“The company expects remaining performance obligations to grow more than 10 times year-over-year in the second quarter of 2026 to more than $800 million — that’s a step-change in visibility and revenue quality. This is not a one-off AI pop; it’s infrastructure demand with multi-year staying power.” — Cantor Fitzgerald (paraphrased, strongest line)
Cantor also points to the Russell 1000 inclusion as a liquidity catalyst. PMs should appreciate that: forced buying from index funds is a real tailwind for a name that’s still small relative to hyperscalers.
UBS’s concern is more structural: how much of this is pull-forward? If the Richmond 6MW is already utilized, the incremental 20MW in 2027-28 is priced in. The stock already trades at a massive premium to data center peers — 365% in one year means the re-rating is complete. Upside from here requires capacity additions beyond the 20MW announced, or even bigger AI-native logos. That’s a high bar.
DOCN is a real story — the AI inference tailwind is genuine, and the RPO explosion confirms it. But the r/r here is lousy for a long at current levels. The bull case is consensus, the PTs are getting cut, and outsized upside requires execution that isn’t in the pre-announce. Wait for the full print and a dip to re-enter. If it pulls back to $120-125, that’s where the risk/reward flips back.
VERDICT: SHORT REPORT PULLBACK LOOKS OVERDONE, BUT THE SCANDIUM STORY ISN'T GOING AWAY. Stock’s down ~12% from the July 2nd high ($289) after the Hunterbrook hit piece. Baird and Mizuho both held ratings/PTs – that’s the floor. The debate is whether the speed-to-power AI narrative can outrun supply chain scrutiny.
Short report landed Tuesday, focused on scandium sourcing, China dependence, and recycled Brookfield financing concerns. Stock got clipped, but both sell-side shops responding today say the pullback is overdone.
Mizuho (Neutral, $285 PT) – The most measured take. They acknowledge the delays highlighted in the report are mostly customer/permitting related, not Bloom’s fault. They think the report overlooks the core value prop for AI data centers: speed to power. Still, Neutral says they’re not pounding the table.
Baird (Outperform, $310 PT) – More aggressive defense. They call the report a recycling of old bear arguments. Point to COO Chitoori’s blog post on July 7 confirming scandium is sourced from industrial tailings (nickel, titanium, bauxite waste streams – same as CPM Group’s 2022 independent research). Bloom says current supply chain can support 25GW of production; the short report focused on 5GW nameplate at Fremont. That’s a massive gap in the bear case.
“The short report recycled several bear arguments, with the scandium concern stretching back many years. Bloomberg’s COO addressed it directly – tailings-based sourcing from industrial waste streams. The market overreacted.” – Baird analysts
Other analysts in the mix: UBS ($350 PT, Buy – post Brookfield expansion to $25B), Jefferies ($246 PT, Hold – sees EBITDA to $4.3B by 2030, still below consensus), Wells Fargo ($217 PT, Equal Weight – cautious on valuation). The bull camp is louder, but the spread is $217-$350. That’s a 60% range from floor to ceiling.
BULL: Speed-to-power for AI data centers is real. Brookfield $25B partnership provides financing oxygen. Scandium supply is a non-issue at scale – it’s a by-product, not a mined commodity. Stock has 786% 12-month return and still has room if AI demand accelerates.
BEAR: The shorts are asking the right question – where does the scandium really come from? CEO statements about “not depending on China” contradicted by supplier data. Backlog vs. RPOs, CFO churn, New Mexico pipeline delays – these aren’t new but they’re not resolved. At 60x next year’s EBITDA (consensus), any supply chain hiccup kills the multiple.
This is a momentum name with a catalyst (Q2 earnings July 28) and a short report that landed during a quiet period. The range of analyst PTs ($217-$350) is massive – tells you conviction is low but the bull case is asymmetric. If you’re long, you hold through the headline noise. If you’re not, wait for the July 28 print to see if backlog conversion is real. The scandium story won’t be settled in a week, but Bloom’s AI pipeline is the only thing that matters for the next leg.
VERDICT: THE WORLD CUP IS THE EXCUSE, BUT THE REAL STORY IS SLOWING ENGAGEMENT AND A CONTENT PIPELINE THAT CAN’T REPEAT THE SQUID GAME / STRANGER THINGS MAGIC. Two analysts, one Outperform (Bernstein, $100 PT), one Hold (Benchmark, no PT) — and both are effectively saying the same thing: Q2 is soft, and H2 catalysts are unclear. Stock at $75, 6% off the 52-week low of $70.86. The bull case rests on H2 margin comps and a potential acquisition (Roku bid failed — Fox won at $20B). The bear case is that subscriber growth is structurally decelerating and advertising revenue ($3B guided) isn’t filling the gap.
Bernstein’s note is the more detailed of the two. Their analyst:
Benchmark’s analyst (Kurnos) stays on the sidelines:
"Third-party data signals suggested engagement was starting to show weakness following recent price increases."
He flags that valuation (20x 2027 GAAP) is a premium to broader market in an AI-obsessed tape. He sees potential catalysts in H2 margin easy comps or an acquisition that boosts engagement — but notes the Roku deal fell through.
BULL: World Cup drag is a one-time event. NFLX is still a $318B streaming giant with $3B ad revenue scaling, and at ~20x forward earnings it’s cheap relative to historical multiples. H2 margins have easy comps. If they land 2030 World Cup rights or announce a meaningful acquisition, the narrative flips overnight.
BEAR: Engagement is the canary in the coal mine. World Cup just accelerated a trend — the content pipeline is getting weaker, not stronger. Subscriber growth is decelerating even with price hikes, and ad revenue isn’t material enough to offset. The stock at $75 is a value trap, not a bargain.
Bernstein on the strategic implications of live sports:
"Second-quarter engagement declined into June as the World Cup pulled viewers away from Netflix and other streaming platforms. The firm said this pressure reinforces why live sports and event programming matter strategically, noting Netflix is reportedly in talks for 2030 World Cup rights."
Translation: they’re using a short-term headwind to justify a long-term thesis — but the thesis only works if Netflix actually wins those rights. Meanwhile, the Q2 print on July 16 is going to be ugly. Don’t buy the dip before then unless you believe H2 can surprise. I’m not there yet.
BUY. The Mexico deal is the right move at the right price. Stock’s down 37% from highs — that’s the entry, not the thesis breaker.
Stifel and UBS both reiterated Buy this morning after EFX announced the $750M acquisition of Círculo de Crédito (Mexico’s only bureau licensed for both consumer and commercial). Stifel holds at $235, UBS at $220. Mizuho cut to $210 citing “AI disruption fears” — feels like noise relative to the fundamental step-change here.
Bull: This is a structural growth asset in an under-penetrated market. EFX’s cloud-native architecture + Círculo’s alternative data = a product cocktail that incumbents can’t replicate. 39 new patents in 1H26 (AI/identity/fraud) reinforce the tech differentiation.
Bear: Integration risk is real — Mexico is not Brazil. And the stock’s been shellacked on AI displacement fears. If the macro softens, consumers default, and credit bureau volumes dip, the multiple compression could accelerate before any Mexico benefit shows up.
“The acquisition would allow Equifax to enter the under-penetrated, fast-growing Mexico market.” — Stifel
That’s the thesis in a sentence. The alternative data angle is the real unlock — Círculo is the only game in town for non-traditional credit scoring in Mexico. EFX gets a data monopoly that doesn’t exist in the US.
Worth noting: stock traded ~$174 at Stifel note, ~$169 at UBS note. That’s a 3% intraday move on the same catalyst. Not sure we can read too much into that other than algos being slow to price a $750M deal in a $20B market cap name. Watch for follow-through.
Bottom line: EFX is trading like the Mexico deal is a rounding error. It’s not. This is a multi-year compounder catalyst. Skip the AI hysteria — buy the data moat.
Verdict: MKSI gets a modest PT nudge to $415 from $400 — but the real signal is the WFE spend growth trajectory Mizuho is baking in. Stock already up 232% over the past year at $377, so the upside is thinning but the narrative still has legs. Mizuho now sees 2027 global WFE at $192B (+25% YoY) and introduced 2028-29 estimates of $221B and $214B. The driver: memory spending (HBM capex accelerating into 2027-28) and advanced packaging constraints.
"Mizuho cited a growing supply-demand gap due to a global memory shortage."
TSMC CoWoS capacity is expected to hit ~140K wafers/month by YE 2026 and over 200K by YE 2027 on GPU/ASIC ramps. That’s a direct tailwind for MKSI’s critical subsystems in etch, deposition, and packaging. BMO also initiated Outperform recently, citing broad semi-cap exposure. The bear case? At these multiples, any WFE revision lower (memory cycle peak) would hit hard. But for now, the rate of change in CapEx estimates is still positive.
Baird initiates Outperform with $65 target, but the real story is the rate of change. COHU is up 155% in the past year and 124% YTD. That’s pricing in a lot — but the thesis is still about acceleration, not just a recovery. Baird sees AI-driven demand across HBM inspection, power management IC test, and software analytics. And they’re not alone: TD Cowen went to $80, Stifel to $50, Needham to $54, Jefferies to $60 — all Buy. The consensus is building that the trough is behind us.
"Cohu is positioned to benefit from AI-driven demand in high-performance computing, HBM inspection, software analytics, and power management IC test."
The key variable is margins. Consensus expects a return to profitability this year (EPS $0.61) after a LTM loss. That’s a big swing factor. If the Q2 guide (revenue $144M, +15% QoQ) is real and the second-half ramp holds, the stock has room. But at 85x forward earnings, it’s priced for perfection. The bull case requires the AI test cycle to be more than a spike. So far, the order flow ($5M DiamondX for GaN power devices, AI compute evaluations) suggests it’s real. The bear case: core automotive/industrial recovery is still tepid, and this thing could get cut in half if AI spend pauses. Right now, momentum wins.
TD Cowen comes out of a lunch with Jensen & Co. and says the market is still too narrow on this name. They reiterated Buy, $275 PT, Top Pick. The core message: compute is still in shortage (rising legacy GPU rental prices, premium cloud deals), and NVDA’s hardware-software co-design is the structural moat the market is underappreciating. $4.89T market cap, 70% revenue growth, 74% gross margin — the scale is almost numbing, but the bull case is that the AI infrastructure buildout is still in early innings.
"Nvidia communicated that compute remains in shortage... the market is framing Nvidia’s technology stack and opportunities too narrowly."
The bear case gets a token head nod with the Burry short and Zuckerberg’s “slower AI agent progress” comment. But BofA calls the recent semi pullback a temporary adjustment, and the $20B Vera CPU revenue target (vs. Intel/AMD turf) plus the nuclear data center deal are incremental positives. Nothing here changes the narrative — the rate of change in AI spend is still accelerating, and NVDA owns the pickaxes.
PENALTY BOX, BUT THE SETUP IS IMPROVING. Cantor reiterated Neutral at $110 (21% upside from $91.10) after the stock flipped from consensus long to "more mixed" post-SYNA acquisition and no preannouncement. They see messaging supporting cyclical recovery, DC power upside, and margin expansion — model gross margins at 42% exiting the year (already 42.67% LTM, so maybe conservative). 2028 stretch EPS of $6, discounted back, justifies the pullback.
"The stock was a consensus long position a couple of weeks ago. Following the SYNA acquisition announcement and lack of preannouncement, positions are now more mixed."
Other analysts are split: Needham raised PT to $130 (Buy, more optimistic on SYNA pairing), while UBS ($95) and Stifel ($107) remain cautious/Hold. The Fab Right divestitures (Philippines, Pennsylvania) are incremental but not needle-moving. 27 earnings revisions higher is a positive signal, but the acquisition overhang and lack of near-term catalyst keep this a show-me story.
Evercore just shoved the target to $415 from $320 — and they’re far from alone. FBN to $330, Needham to $425, William Blair bumping FY26 FCF estimates to $4.2B. The collective thesis: platform consolidation is real, AI-powered security ops are sticky, and SASE/Cortex are gaining share. Stock’s UP 83% YTD, but Evercore sees room at 52x CY27 FCF assuming durable mid-teens growth and expanding margins.
“Partner feedback was broadly constructive… highlighted sustained platform momentum and stronger identity conversations with CYBR.”
That identity angle with CyberArk is the new narrative twist — watch for cross-sell data next quarter. 41 analysts have revised estimates up. At $318, this thing still has r/r if you buy the platform moat.
TD Cowen just threw a massive valuation bridge at the wall. Raised PT to $700 from $525, stock at $570. But the real signal is the WFE scenario work: $250B by 2028, $400B by 2030. That’s not a base case — that’s the bull case they’re comfortable publishing. Memory fab ROI is 3x better than prior cycles, and demand is locked in via take-or-pay. AMAT is the primary beneficiary here on leading-edge front-end and DRAM exposure.
The firm models AMAT EPS of ~$25 in a $250B WFE world (vs. their 2026E of $13.35). At $400B WFE — which requires a NAND turnaround later this decade — they see low-$40 EPS. That’s a 3x earnings ramp from current estimates. Lam and KLA also get big numbers but AMAT gets the first call.
“Under a $250 billion WFE scenario, Applied Materials’ earnings could approach $25, up 1.9 times from the firm’s calendar year 2026 EPS estimate of $13.35.”
Counterpoint: Michael Burry’s short disclosure on AMAT is out there, alongside shorts on NVDA and TSLA. He’s calling overvaluation on the AI capex narrative. Options flow was heavy yesterday — 80k contracts, skewed calls 62/38 — so the retail/short-dated crowd is still long. TD Cowen’s $700 PT implies ~23% upside from here. Not sure we can dismiss the Burry signal entirely, but the structural WFE story (take-or-pay, AI-driven DRAM density) has more fundamental weight than a single short bet.
Verdict: Two strong buy endorsements on the same name – Stifel reiterates Buy at $784, Oppenheimer just upgraded to Outperform at $800. Both are pointing at the same catalysts: grid hardening, renewables buildout, IRA fiscal stimulus. Stock has already ripped 75% in the last twelve months, but the thesis isn't tired yet. PWR sits at $666, so there's still ~15-20% upside to PTs. The key is that this isn't just a "capex cycle" narrative – PWR is structurally de-risking its earnings profile.
"Strategic efforts to shift toward more stable small-to-medium base work and high levels of self-perform work above 80% are expected to reduce earnings volatility."
Self-perform >80% and moving away from lumpy large projects is the right slide. That plus rising free cash flow conversion (driven by renewables) should support the valuation multiple – which is the main pushback at 91x P/E. Hard to justify that on face value, but if earnings quality improves and growth sustains, the multiple compresses over time. Oppenheimer’s upgrade (from Perform) adds incremental conviction. Light day on PWR but the signal is clean: infrastructure trades are still on, and the shift to higher-quality recurring revenue keeps the bid under the stock.
NVT is Bernstein's top pick into earnings (21 days out). PT bumped $2 to $220, still Outperform. Stock up 107% over the past year at $160 – not cheap, but earnings beats still in play.
The thesis: data center liquid cooling capacity ramp is underappreciated, driving upside in SP segment. Margin fears are real (recent quarters), but Bernstein sees operating leverage and EC pricing/productivity fixes as the antidote.
"Expectations are elevated among investors who follow the stock but we see potential for positive surprises, particularly as liquid cooling capacity increases." — Bernstein
UBS also out with Buy, citing >25% organic sales growth in Q2. Add in the Siemens/Nvidia AI factory blueprint, and the narrative is sharp. Risk: orders uneven – watch the SP segment prints.
Verdict: Cantor likes the setup into earnings (Aug 4) but admits the narrative needs a spark. Stock's up 33.5% YTD on a beat/raise baseline, yet positioning is still underweight. That's a low bar. The real unlock? Data center clarity or a named PCIe win. Without it, this is a mean-reversion trade in a stock that’s been dead money for a year.
Cantor reiterated Overweight, $125 PT (49% upside from $84.15). They see EPS tracking to $6 in CY2028. But they’re honest about the rub — what actually changes the story? Industrial/Auto/Defense exposure is fine, but the Data Center segment is only ~7% of revenue. J Capital flagged that exact point yesterday in a cautious note. So the bull case rests on that 7% becoming material.
"The firm stated it feels positive about the likelihood of a beat and raise but questioned what would change the broader narrative for the company."
Worth watching the free compiler tools announcement — not a needle-mover alone, but it removes a friction point for developers, could help ecosystem stickiness. The DSA504RT rad-tolerant clock generator for space is a nice niche win. QML Class Y cert in Nantes adds cred in defense. All slow-burn positives.
Bottom line: Cheap stock, overlooked, but the catalyst path is narrow. If you’re playing earnings with a short-dated option, the r/r leans skewed with that underweight positioning. If you need a structural thesis, wait for data center revenue disclosure to prove out.
New PT of $185 from BofA (was $180) — joining a $180-185 cluster with Barclays and Evercore. Not breaking new ground, but the call is about durability, not acceleration. The stock's up 62% in the last year, and the bull case here is that it stays a compounder.
Revenue PRINTED $7.62B vs $7.08B consensus. Orders hit $9.4B — up 78% YoY. EPS $1.06 vs $0.94. That's a beat across the board, and guidance for Q2 ($8.15B sales, $1.15 EPS) is another $0.10 above the Street. Execution machine: organic incremental margins above 30%, double-digit organic growth.
The three investor concerns — AI durability, copper vs. optical, share risk — are "manageable" per BofA. Couldn't agree more. Amphenol's content sits across too many programs for any single timing shift to matter. And beyond AI, most end markets are healthy.
"The firm said investor focus centers on the durability of AI growth, copper versus optical technologies, and potential share risks, but views these concerns as manageable."
CCS integration will get updates through 2026, then the stand-alone disclosure likely tapers in 2027. That's fine — the story is about organic compounding plus M&A, not a single bolt-on. $185 target is a ~17% upside from here. Not screaming cheap, but for a name that keeps beating and raising, the r/r is fine.
BUY THE PULLBACK. DA Davidson reiterates Buy / $74 PT (35x 2027 EBITDA) after the 11% weekly slide to $57.20. Stock still up 121% YoY. Thesis: multiple levers to beat consensus in 2026-2027 — data/analytics/orchestration combo solving supply chain pain points. The 20% revenue CAGR target through 2030? They call it "achievable and potentially conservative."
"the company’s target of a 20% revenue CAGR through 2030 as achievable and potentially conservative"
Caveat: public offering overhang (3.8M shares, 500k from the company) caused a 6.9% one-day drop a bit back. Not sure that's fully digested yet — watch secondary flow. Rosenblatt also raised PT to $52 (from $47) after Q1 beat (EPS $0.31 vs $0.21 est). That's not huge, but shows sequential confidence upgrades.
Bottom line: high-growth semi tool/services name with a differentiated analytics angle. Risk/reward asymmetric if they sustain that CAGR. The 35x EBITDA multiple isn't cheap, but the rate of change on orders/recurring revenue is the real swing factor. Keep on radar.
B.Riley throws a massive PT hike at BAND — $85 from $55, Buy reiterated — and the thesis is pure AI voice infrastructure. Stock is already +340% over the past year to $70.49, but the analyst sees more runway as frontier model developers (OpenAI, Google, xAI, Microsoft) all push voice agents into production. BAND’s digital voice specialization makes it the toll road for carrier-grade AI voice traffic.
"The focus on AI voice technology by frontier model developers and large-scale enterprise software developers supports our view that AI voice will become a primary mode of communications with AI software."
Convertible notes ($275M, 0% coupon) and the new Bandwidth Build platform (lets AI agents autonomously deploy voice services) reinforce the narrative — they’re funding the infrastructure buildout to capture demand. New CRO hire from Vonage adds enterprise SaaS credibility. The catalyst path is clear: every AI voice agent that needs a phone number or a PSTN connection pays BAND.
Verdict: Truist upgrades to Buy after the 24% post-merger announcement wipeout. They see a buying opportunity despite slashing the PT to $75 from $90. The move looks like a timing call — the selloff overdone, the ESI acquisition (valued at ~$14.5B) brings real cross-selling and FCF acceleration. PMs: this is a classic "hated deal, paper hands shaken out" setup.
"The transaction will strengthen Solstice’s electronic materials business and improve the company’s earnings and free cash flow growth."
Merger math: ESI shareholders get $10 cash + 0.5 SOLS shares (~$50.10 total). Freedom Broker downgraded ESI to Hold post-announcement (modest premium), but BMO and BofA kept Buy/Outperform on ESI’s standalone strength. Truist maintained Buy on ESI too — so the upgrade on SOLS is effectively a bet the combined entity de-risks quickly. Cross-sell optionality is the hook, but the market needs to see execution before the stock recovers. Rate of change works against them short-term; long-term, the multiple could re-rate if the deal closes cleanly.
TD Cowen thinks the WFE cycle has legs — and KLA is one of the best seats in the house. Raised PT to $260 from $200 (stock at $221, up 82.5% YTD). Their math: $250B WFE by 2028, $400B by 2030. Under the $250B scenario they get $9-10 EPS (vs ~$3.53 trailing). Under $400B, mid-teens EPS. The memory ROI narrative is doing heavy lifting — 3x better than prior cycles, and demand is locked in.
“Demand is committed through ‘take or pay’ agreements in the memory sector.”
Valuation is the obvious pushback. 63x trailing P/E. Even the $260 target implies ~17% upside from here, but that’s betting on a multi-year WFE supercycle. Cantor Fitzgerald’s $2,000 PT is either a typo or a different base case (ignore that line). Moody’s affirmed A2 with positive outlook — supportive but not a catalyst.
Bottom line: Thesis is fine for a 12-18 month hold, but the r/r tightens fast if WFE prints soft even one quarter. Memory “take or pay” is a real moat — just don’t confuse multi-year potential with near-term alpha.
KEYBANC GOES TO SECTOR WEIGHT — calls the Agentforce acceleration timeline "further out" than the market expects. The downgrade is a real slap: they’re the most channel-immersed firm covering Salesforce, and they’re saying customer feedback is consistent on two fronts — data isn’t ready, and the product isn’t ready. Stock at 19x P/E with a 0.49 PEG looks cheap, but that’s a value trap if growth doesn’t inflect.
"Customers’ data is not organized to do meaningful AI work, and Agentforce as a product is not ready."
KeyBanc also flags that more CIOs expect to deprioritize Salesforce in their IT budgets over the next 12 months than prioritize it. That’s a problem for the re-rating story. Counterbalance: Guggenheim and Monness upgraded this week on valuation, calling the current level an attractive entry. But those are pure valuation calls — no channel evidence. The KeyBanc piece carries more weight given their access.
Bottom line: Agentforce is priced in as a 2026 catalyst. If it slips to 2027, the multiple compresses further. The Fin acquisition ($3.6B for Intercom) adds capability but doesn’t solve the near-term growth gap. Watch for mgmt to reset expectations on the next call.
Bullish on the re-rate. Everus gets another analyst stamp of approval (Stifel reiterates Buy, $172 PT) — this on top of Oppenheimer's recent Outperform initiation at $185. The thesis is straightforward: pure-play electrical/mechanical inside data centers, which is where the spend is sticking. The spin-off is unlocking FCF for M&A and organic investment, and the backlog is chunky enough to give multi-year visibility.
The numbers back the narrative. Revenue grew 29.7% LTM, and Q1 2026 EPS printed $1.14 vs $0.48 consensus — a beat that screams operating leverage. At $6.85B market cap ($134.30), ECG trades at a discount to its growth trajectory. The $172-185 PT cluster implies 28-38% upside.
"Everus maintains an elevated backlog, which provides visibility into operations over the next several years."
Risk to watch: Data center capex cadence (if hyperscalers slow, ECG gets hit hard — they're not diversified). Also, spin-off execution risk on M&A integration. But right now the rate of change is positive, backlog is growing, and the Street is still playing catch-up on estimates (2 upward revisions in the last 30 days).
“The firm sees meaningful upside potential to current estimates for the semiconductor company… highlighted an under-appreciated power opportunity for Analog Devices and noted strong leverage to AI spending.”
THE HOOK: Industrial/auto cyclical tailwinds + AI power content = multi-year compounder at a reasonable multiple. The 19x CY’28 EPS is the key — if estimates keep moving up, that PT goes with them. Risks? Execution on Empower integration, broader semis demand if macro softens. But the rate of change here is positive, and the narrative is finally catching up to the stock.
Truist bumps NOW PT to $130 (from $120), stays Buy. The call is straightforward: enterprise AI adoption (courtesy of Claude Code and coding assist) is real and accelerating in H1, and the runway outweighs any optimization headwinds in H2. Truist sees NOW as a 2H winner alongside SNOW, leaning on its broad platform footprint and “enterprise context” positioning — a key differentiator as infrastructure vendors scramble to price on outcomes, not seats.
“The runway for continued enterprise adoption outweighs potential optimization impacts on overall spending in the second half of the year.”
Stock sits at $107.88 — PT implies ~21% upside. Bifurcation trade resumes post-Q2; Truist is betting NOW is on the right side of it.
LASR IS A PURE-PLAY DEFENSE THEME NOW, AND THE MARKET IS PRICING IT. Needham bumps PT to $90 from $80 after the Pentagon directed energy award — $44M initial, up to $627M program ceiling. Stock ripped 27% to $74.71, YTD +99%, 1yr +298%. That’s a lot of multiple expansion already baked in, but the narrative is clean.
“As the only pure-play in what most agree will be a large market, Nlight deserves a premium valuation.”
Expect ~$44M to hit H2 2026 for 150kW prototypes. Then 300-500kW iterations in 2027+. Needham gets constructive on 2027/2028, and Stifel chimed in earlier at $85. Q1 EPS beat by 11c ($0.20 vs $0.09), rev $80.2M vs $72.1M — defense +69% y/y, industrial +32%. Options activity spiked too (put volume highest since Nov 2020, though that’s more hedging than conviction).
Risk: You’re paying for a hockey stick that’s years out. The $627M ceiling is a program ceiling — not a guarantee. And 27% in one day suggests the easy money might be in. But as directed energy plays go, LASR is the only ticket in town. Keep on radar for pullbacks.
BL getting crushed — down 50% in six months to $28.52, market cap sitting at $1.66B. DA Davidson cuts PT to $30 (from $35) and keeps Neutral. The thesis: field checks confirm competitive moat and the pricing shift is actually getting positive feedback, but AI upside is a mirage. "Limited upside from AI initiatives going forward" is the key line. The old growth narrative (AI automation of finance workflows) isn't materializing fast enough to justify the 67x P/E, so the stock is pricing in tepid execution.
"The firm sees limited upside from AI initiatives going forward."
Cantor and BofA already flagged the same concerns — PTs dropped to $36 and $26 respectively, with BofA outright Underperform. Consensus is converging on a show-me story. BL beat Q1 (EPS $0.56 vs $0.45 est, rev $183M vs $181M) but the market didn't care. One-time revenue benefits masking underlying deceleration. At $28.52 and a $30 target, the r/r is dead flat — no catalyst to break out, no margin of safety to short. Neutral feels right for a name that needs either a comp multiple reset or an AI catalyst that actually lands.
HSBC trims PT to $170 from $176 — but the Buy stays. They’re cutting FY27-28 revenue estimates on China commerce retail weakness, partially offset by a more bullish cloud view. The cut is modest (~3-4% on EPS) and driven by higher AI investment spend, not a demand collapse.
THE THESIS ISN’T BROKEN. HSBC still calls BABA their preferred AI name in China. They see catalysts in cloud growth acceleration, margin expansion from in-house chip adoption and price hikes, and advancing AI models. The real line to watch: “If China e-commerce earnings bottom in the June quarter, further re-rating is possible.” That’s the swing factor — not cloud, not AI — but whether the core retail business stops bleeding.
“Alibaba’s share price could see further re-rating if China e-commerce earnings bottom in the June quarter, implying limited further downside to earnings.”
The stock is at $108.98, up 17% from its monthly low but still down 27% over six months. The HSBC cut is noise — the narrative is all about Q2 earnings as the potential inflection point for domestic e-commerce margins. Jefferies, Benchmark, and Bernstein are all Buy-rated with targets $185-220, so the Street is still constructive. Cost discipline + narrowing quick commerce losses are the near-term cushion.
Bottom line: HSBC is hedging on timing, not conviction. The June quarter print is the next real catalyst. If retail earnings stabilize, the cloud+AI re-rating story gets the green light. If not, expect more PT cuts and another leg lower.
Neutral initiation from William Blair — Market Perform, nothing to get excited about. The firm sees AMD as a clear AI infrastructure beneficiary (revs from $52B in 2026 to $104B in 2028, EPS approaching $20 by then) but can’t ignore the massive competitive headwinds. NVIDIA’s GPU moat is still thick, hyperscaler ASICs are gobbling share, and Arm is now a real threat in CPUs — already ~20% of global server. Intel is a zombie for now but will wake up in two years. The thesis is balanced: strong demand, but valuation at 33x 2027E is already a slight premium to peers, leaving limited upside if any one of those risks crystallizes.
“Valuation reflects strong AI computing demand balanced against risks including increasing competition, supply tightness, and a potential slowdown in AI spending growth.” — William Blair
Meanwhile, the momentum crowd is still piling in: Wells Fargo to $615, Cantor to $700, UBS to $670 — all citing server CPU momentum. That’s a lot of optimism baked into a stock that’s already up 274% in a year and trades at 172x trailing earnings. Rate of change on the bullish side is still positive, but the bar is getting high. If the AI spending narrative stumbles or Arm eats any more server share, this multiple compression story gets ugly fast.
Jefferies nudges DTE PT to $172 (from $168), but the real signal is the re-rate thesis. They’re leaning into DTE Electric’s “stay-out” proposal as a differentiator against rising affordability pushback. Stock at $151, ~14% upside to target, already near 52-week high. Market cap $31.5B, P/E 25x – not cheap, but the data center narrative is the hook.
“Execution on the data center opportunity and greater confidence in the stay-out materializing should drive further multiple re-rating.”
Jefferies models an 8.3% EPS CAGR from 2026-2030 vs. DTE’s base 7.2% and consensus 8.1%. The $4 PT increase is driven by electric P/E multiple expansion, not math changes. That’s a bet on regulatory goodwill and data center load materializing.
Broader note flags rising local opposition to data centers nationally (Midwest/Southeast still favorable). DTE’s stay-out proposal is the counter – less rate shock, more political cover. Also, 56-year dividend streak (3.08% yield) gives some buffer.
Takeaway: DTE is a re-rate story riding on data center execution and regulatory finesse. Weak Q2 is noise. The 8%+ CAGR path is credible if Google lands and a third deal drops. PMs who want utility exposure with a growth kicker should watch the July 23 print for confidence signals.
Wolfe stays out on a limb. Reiterates Outperform and $800 PT despite raising FY27 capex estimate to $220B — a massive leap (source says from $15B, which reeks of a typo, but Street was at $160B+). Wolfe sees the stock at $593, down 25% from the 52-week high, and argues Meta must show durable non-ad revenue to justify the spending. They flag a potential capital raise (debt or equity) as a real possibility.
“Meta will need to demonstrate incremental, durable non-advertising revenue sources and frame return on invested capital for investors to gain comfort with elevated spending levels.”
Other signals cut both ways. Erste upgrades to Buy on AI capex momentum; Truist reiterates Buy on Muse Spark distribution. But Zuckerberg admitted AI agent progress is slower than hoped, and Burry is short AI-infrastructure names (so META gets caught in the cross-current). The bulk of the thesis now rests on whether Meta can turn this capex into something that ROIC math makes sense of.
Multiple upgrades rolling in. Wolfe (to Outperform, PT $188), RBC (Outperform), Bernstein (Outperform), and Truist (Buy, PT $208) all leaning in — the collective thesis is that U.S. tower disruption from carrier consolidation is largely behind us, setting up more predictable organic growth. AMT's PEG of 0.45 relative to large-cap REIT peers adds a valuation tailwind no one's ignoring. The DISH churn and refinancing headwinds into 2026 are acknowledged but increasingly seen as priced-in noise.
"The U.S. tower market moving beyond disruption from carrier consolidation sets the stage for more predictable organic growth." — Wolfe Research's Andrew Rosivach
NXPI is the value play nobody wants to own – and that's exactly why Cantor is doubling down. They reiterated Overweight and $400 PT (21x CY28 EPS discounted back) after earnings, arguing the auto overhang is masking real earnings momentum. The firm sees CY27 EPS tracking above $18 vs consensus $17.66, and CY28 upside to ~$20.50.
The valuation gap is the whole story. Analog semis trade at 28x NTM on average. NXPI prints 17x. That's a 39% discount for a company with through-cycle resiliency and secular growth (SDV, radar, connectivity) that Cantor says is "under-appreciated."
"The company's through-cycle resiliency and secular growth opportunities remain under-appreciated by investors."
The bear case: auto exposure is a narrative headwind that won't lift overnight. The bull case: numbers keep grinding higher and the PE multiple eventually re-rates toward peers. Right now the r/r is asymmetric – you're getting a 25% free cash flow yield on a semi that's actually growing earnings.
VERDICT: TSLA IS TRADING ON OPTIMUS OPTION VALUE — and Citizens is the latest to say the options market is pricing in a faster commercialization timeline than the engineering reality supports. Initiated at Market Perform from Andrew Boone, the note is basically a long-term bull case (robotics is the largest opportunity in their coverage universe) wrapped in a near-term reality check (markets are too optimistic about the complexity of shipping a humanoid robot at scale).
The physical AI thesis is real. Boone correctly argues the building blocks — AI/world models, faster chips for edge compute, and emerging robot capabilities — are finally in place. TSLA has all the assets: leading autonomy models, in-house silicon, advanced manufacturing, batteries, and Musk's engineering DNA. That's the 10-year story.
The catch? "This grand vision will take time to achieve." The firm thinks Optimus introduces a new level of production complexity, expects delays, and sees TSLA at the beginning of an investment cycle — not the end. At a $1.48T market cap, the stock is already discounting a lot of optionality. The near-term r/r is ugly if Optimus hits a single roadblock.
"The firm said it expects Optimus to incur a new level of production complexity, with delays and greater spending, and views Tesla as being at the beginning of an Optimus investment cycle."
The delivery beat (480K units, +25% YoY) is noise for the long thesis. This is a robot/AI story now, not a car story. The market cap says PMs are already there on the vision. The question is whether the timeline gets stretched — and if the stock can hold this valuation through an investment cycle that hasn't even started yet.
Expensive but reliable — and finally seeing data center revenue hit the P&L. Bernstein nudged PT to $555 from $550, Outperform, calling TT a low-to-mid-teens EPS compounder. The key catalyst: large applied HVAC orders from data centers starting to materialize this quarter. That's been the narrative for a while; now we get to see if it prints.
"Large applied HVAC orders growth driven by data centers could begin materializing into revenue this quarter."
Margins are on watch too — Bernstein sees Americas incremental margins ~30% and Q2 EPS of $4.28, slightly above guidance. Level loading of residential production helps the comp. The catch? You're paying 35.7x earnings and a PEG of 4.73. That's not cheap. But for a name that runs the HVAC book in a structurally growing end-market (data centers, energy transition), the premium has held. KeyBanc also at $555, Overweight. New COO Donny Simmons consolidating ops — don't expect a strategy pivot, just execution.
Bottom line: Data center tailwind is the rate-of-change driver. If Q2 shows revenue conversion, the multiple stays. If not, that PEG ratio becomes a liability.
MIXED BAG OF COVERAGE STARTS, BUT BULLS HAVE THE EDGE. RBC initiates Outperform and $435 PT, echoing Bernstein's recent call at the same target. Both see a genuine turnaround story in the BD acquisition and a structural tailwind from drug manufacturing (~15% of sales). Piper Sandler is neutral at $400, acknowledging the strategic evolution but probably balking at the 54x P/E. That valuation is the obvious friction point – the market is pricing in a lot of execution. Short interest just spiked (TD Cowen data), which feels like crowded skepticism on an already-high multiple.
"A positive view of the turnaround opportunity within the recently acquired Becton Dickinson businesses"
The BD piece is the swing factor. If management can wring out the synergies, the premium multiple becomes defensible. Reshoring demand adds a nice optionality layer. But at 54x, a single miss and the air pocket gets real. Still, two out of three new analysts saying "buy" at $435 gives the narrative some momentum. Watch for the next print to validate the thesis.
UBS stays the course. Reiterates Buy and $275 PT on ACN despite a 52% y/y drawdown to $140.99. The catalyst is the Google Cloud partnership – prebuilt agentic AI solutions for midmarket firms ($300M-$3B rev) via Accenture Edge. UBS sees this as proof AI deployment is scaling, not just experimenting.
"AI deployment is moving beyond experimentation toward scaled enterprise adoption."
The expansion into midmarket opens a $240B TAM growing high-single-digits. Adds to existing tailwinds: a €200M NATO contract, a ServiceNow-driven legacy-to-AI migration offer, and a Seahawks tech partnership. Cheap at 11.2x P/E with a 4.6% yield – the market is pricing in a margin squeeze that may not materialize if cloud migration spend accelerates.
Verdict: Rosenblatt nicks the PT by $3 on FX — but the broader analyst base is leaning into the AI/product cycle. The Neutral rating stays, but the action is noise. The real question isn't Q2 print (expected in-line) — it's whether the new features and premium tiers can move ARPU off the dime.
"Artificial intelligence appears more likely to help than challenge Spotify"
That's Rosenblatt's take, and it aligns with the more aggressive bull case from Citizens ($625 PT), Cantor ($520, citing AI roadmap with UMG), Benchmark ($695), and Bernstein ($625). The divergence is just valuation conviction — the narrative is converging: AI as a tailwind, not a risk. Currency is a speed bump. PT range from $520 to $695 tells you where the real debate lives.
Verdict: Drone/edge computing play with two analysts now pounding the table. Canaccord raised PT to $11 (from $10.50) – that's >100% upside from $5.33 – and Needham initiated Buy. The thesis is pure government spending: $74B in planned reconciliation legislation for drones/c-UAS, plus $70B already passed for DHS. That's ~$144B in earmarked dollars.
The Vecima industrial IoT acquisition ($11.5M, adds $5.3M rev including $4.5M ARR) gives cross-sell optionality on modems and 125k asset tags. Canaccord slaps a 3.1x EV/rev on FY27 $142M (post-acquisition) to get to $11. Stock already up 77% in the past year, but still trades at a discount to IoT comps like Itron (11.6x EBITDA). EPS turning positive this year ($0.16) helps the narrative.
"The analyst noted $74 billion included in planned reconciliation legislation for drones and counter-unmanned aircraft systems, plus $70 billion in reconciliation funding passed for the Department of Homeland Security last month."
Risks: The public offering (4.17M shares at $7.20, ~$30M gross) dilutes existing holders. Execution risk on the Vecima integration and margin expansion. But the government tailwind is real – not a typical IoT story. Worth a look for PMs playing defense-tech positioning.
Verdict: Cantor Fitzgerald goes overweight with an $11 target (156% upside from $4.29, basically a 52-week low print). Thesis is pure narrative: first-mover in autonomous flight, military contracts as a certification shortcut, and a pilot shortage that makes the TAM real. Revenue growth of 188% this year is the bogey — but they're burning hard on engineering.
"Merlin Labs benefits from a first-mover advantage in the autonomous flight sector. Military contracts help de-risk the certification path for the technology."
The set-up is clean if you buy the autonomy thesis — C-130J Critical Design Review just cleared, moving to aircraft integration. But Q1 rev was only $1M (+15% YoY) with adjusted EBITDA loss widening. Cash position is "strong" per the platform, but at this burn rate the clock matters. TD Cowen also at $11 buy — consensus target cluster is tight. Low-float, high optionality. Not for the faint of heart, but the r/r checks out if you think FAA/FAA-adjacent cert is real.
Block is a conviction call here. Mizuho reiterates Outperform with $100 PT (30%+ upside from $76.55) driven by survey data showing ~2/3 of Cash App users are likely to engage with Neighborhoods. This loyalty program is management's biggest lever — potentially re-engaging dormant users (50% of followers were previously inactive before joining). The survey gives us some confidence the signal is real, not just management hopium.
"Probably the biggest lever that we have... has the ability to just fundamentally change the size of our network and the trajectory of growth, but we're in early days there."
Survey supports the narrative that Neighborhoods can bend the engagement curve. Baird and TD Cowen both in at $100-101, tacking on product momentum from AI tools and the Square/Sherwin-Williams deal. The 17.6% YTD return is real — this isn't a broken story, just one that needs the follow-through. Upside to $100 implies solid r/r from $76.55 if Neighborhoods actually drives MAU growth.
The "early days" caveat is honest but the survey data weakly supports the thesis. Wait for 2Q print to see if engagement metrics actually inflect.
RBC sticks with Outperform / $655. Thesis is clean: Q2 beat driven by asset-based fees upside. They see potential FY26 FCF guidance raise, even as EBITDA guidance tightens to high end. Index subscription growth reaccelerating to LOW DOUBLE DIGITS, while Analytics moderates to ~5%. Net new recurring subs modeled at $52M (+19% YoY), modestly above consensus of $51M — strong Index momentum doing the heavy lifting.
RBC models net new recurring subscription sales of approximately $52 million, representing 19% year-over-year growth. The figure sits modestly above consensus at $51 million, supported by strong Index momentum.
Analytics facing tough comps, so modest decline in new subs expected there. Upside if retention outperforms vs weak 2Q25 retention. Not a home run story, but steady compounding + FCF flexibility keeps the r/r attractive at 34x.
UBS just bumped Q2 estimates to $0.99 from $0.92 (consensus $0.95) and kept their $120 PT — that’s ~40% upside from here. They’re calling NDAQ their top exchange pick. The thesis: strong volumes across index (+12% forecast) and market services (+12% on higher US cash equity volumes) plus Solutions organic growth accelerating to 14.9%. Add in the H1 listing record ($129.3B, SpaceX alone $85.7B) and the Closing Cross processing $334B in Russell reconstitution — the flow story is real.
“Nasdaq remains UBS’s top exchange pick.”
Valuation is the kicker: 25.9x P/E on a 0.5 PEG. That’s cheap for mid-teens organic growth and a business that prints cash from market structure moats. Not much to dislike unless volumes roll over — but with futures and AUM still growing, rate of change is your friend here.
Citizens bumps PT to $450 from $365, keeps Market Outperform. Reason given: strength across the fintech/digital assets coverage group — but specifically for DAVE, they cite retail engagement, record prediction markets activity, and product velocity. Stock's already ripped +114% over the period they reviewed, +26% in six months, +14% YTD. Market cap $3.18B, financial health score 3.07 ("GREAT"). Soft crypto backdrop is a modest overhang for some names in the group but doesn't seem to dent the DAVE story here.
The entire thesis in one quote:
"retail engagement, record prediction markets activity, and continued product velocity as key drivers."
Nothing else moving the needle on this name today. Single analyst action, no competing takes. The raise confirms momentum — but without a fresh catalyst, it's just a PT shuffle reflecting the stock's own run.
Coinbase getting a PT trim ($355 to $325) from Citizens but they're outright saying this is the one to own for a turn. The soft crypto backdrop is the headwind — lower volumes, tepid retail — but the bull case is entirely about what the Street isn't pricing: 2027 numbers that embed Prediction Markets, agentic finance, and crypto-TradFi convergence. Citizens keeping Market Outperform here is a statement of conviction on the out-year story.
The article tees that up well:
"The pace of blockchain adoption and institutional integration accelerated through the quarter. The firm’s above-consensus 2027 numbers reflect adoption across Prediction Markets, agentic finance, and crypto-TradFi convergence that it does not think the Street yet captures."
The bull case in one line: You're not buying this quarter's volumes, you're buying the structural shift in how financial infrastructure is being rebuilt. The bear case: "Soft crypto backdrop" is the polite way of saying retail engagement is non-existent, regulation is still a drag, and there's no catalyst to re-rate until Bitcoin does something interesting again. Fair enough.
Bottom line: This is the "just beginning to turn" name in Citizens' matrix. In a sector where some names ran 25-50% this quarter, COIN is the laggard with the highest conviction out-year growth. PMs should ask: Do you believe in the 2027 thesis enough to sit through Q2/Q3 noise? If yes, this is the entry.
Upgrade day for BETR. Northland goes to Outperform from Market Perform, PT $38 – and they're not alone. The thesis: market share grab in a soft macro. Elevated rates and oil are headwinds, but BETR is picking up volume through Credit Karma, Coinbase, Stripe, FOA, plus HELOC partnerships and Tinman AI. The cost structure is tightening, too. The firm sees multiple growth vectors at different stages, all gaining traction.
"Well positioned to capture market share despite softer macro conditions"
It's not just Northland. Three other firms already came out on the front foot – Canaccord at $42, BTIG at $36, Roth/MKM at $35 – all citing the AI-native origination platform and partnership flywheel. The Bitcoin-backed Fannie Mae mortgage (first in the US, with Coinbase) is another proof point. PMs should note the rate of change in distribution moats (Credit Karma alone is a massive funnel) versus the drag from a higher-for-longer rate environment. The collective PT cluster is $35-42, so $38 sits right in the meat. If the rate narrative loosens even a little, this thing compounds. If it stays tight, they're still taking share. R/r leans bullish.
Citizens cuts PT to $30 (from $40) but keeps Market Outperform — the cut is mechanical (lower NAV math), not a deteriorating thesis. They see the 68% Y/Y stock decline as a disconnect between ETH price action and real ecosystem adoption. SBET trades at 0.75x fully-diluted mNAV. The call: active balance sheet management (ETH-per-share compounding, yield strategies, stock buybacks) should deliver returns that crush a passive ETH hold.
"The firm views the disconnect between recent ETH price action and the pace of ecosystem adoption as the signal through the noise... Citizens views the company as a coiled spring against renewed ETH demand as the year progresses, with potential CLARITY Act passage serving as an additional material catalyst."
Context: Q1 massive EPS miss (–$3.25 vs. +$0.46 consensus) spooked the tape, but revenue grew 1,628% YoY. They just raised $75M at a 41% premium, bought 10k ETH at ~$1,611, and repurchased >2.1M shares. Beta is a ludicrous 10.5 — this thing moves like a levered ETH proxy with optionality on institutional adoption. The new $30 target implies ~1.35x 2027 mNAV of $22. Not a core PM position, but a high-conviction tail for guys who want convex ETH exposure without trading futures.
The Iridium deal is a bold bet on vertical integration, not a near-term catalyst. Rocket Lab is buying a fully built LEO constellation with 2.6M subs and global L-band spectrum for ~$8B EV (16.8x 2025 EV/EBITDA). That’s a premium to where IRDM was trading pre-speculation, but the stock already ran 178% in six months — so the upside is priced for the arbitrage, not the thesis. The real story is Rocket Lab internalizing launch services and capturing margin on constellation replenishment, plus pushing into IoT, direct-to-device, and resilient PNT. Needham kept a Buy on strategic fit. William Blair downgraded IRDM to Market Perform — the deal premium is modest, and there’s limited near-term upside for IRDM holders once the arb closes. The combined entity is now a one-stop shop from design to comms ops, but execution risk is real: merging a launch startup with a mature satcom operator mid-cycle is hard.
“The transaction combines Rocket Lab’s launch and spacecraft manufacturing capabilities with Iridium’s on-orbit scale and cash flow. The combined entity creates an integrated operator spanning design, build, launch, and satellite communications.” — Jefferies
Not sure we can read too much into the intraday pop — deals this transformative take quarters to digest. Watch for IRDM shareholder vote and regulatory path in 2H. RKLB positioning in the value chain just got a lot larger, and a lot more complicated.
Hold initiation from Freedom Capital with a $59 target — basically a shrug at $57.13. The thesis: healthcare AI is real, growing 37-43% CAGR, and Tempus has 70% trailing revenue growth. But the public HC IT group underperforms the S&P 500, and most generative AI spend flows to startups, not listed names like TEM. So you get a price target roughly in-line with current print. Nothing wrong with the business — just not enough catalyst or relative edge to chase at 10x revenue.
"Physician use of AI has more than doubled since 2023, and over 66 million Americans have used AI to search for health information."
The real signal here might be the absence of a Buy — Freedom sees the TAM, respects the growth, but isn’t pounding the table. Meanwhile TEM continues to ink academic collaborations (angiosarcoma, AFib detection, digital pathology consortia) and has Canaccord repeating an $80 Buy. Mixed tape — Hold vs Buy leaves the stock in no-man’s land until the next quarterly print or a catalyst that shifts the risk/reward.
Verdict: The deal is done – or close enough. RBC downgraded TECH to Sector Perform (from Outperform) while lifting PT to $73 – exactly the Merck KGaA offer price. Stock sits at $70.96, a whisker from its 52-week high of $72.16. Market is pricing in near-certain close. RBC sees no rival bidder, minimal regulatory risk, and notes the $73/sh is fair by comparable life sciences M&A (PeproTech, Abcam, BioLegend).
"The firm said it believes regulatory risk is minimal and the price is fair by relevant comparables."
Other analysts are falling in line – Deutsche Bank and William Blair both downgraded to Hold/Market Perform at the same $73 PT. TD Cowen kept a Buy but that’s a longer-term view. For a PM: the risk/reward here is tight – you’re getting paid the spread to close (roughly 3% annualized if deal closes in 6 months) with a small tail risk of breakup. Not a catalyst-rich hold unless you believe a competing offer emerges (RBC doesn’t). The protein reagents franchise is best-in-class, but that’s now Merck’s problem.
Compass Point trims PT to $40 from $41 but stays Buy. Valuation reset after the stock completely gave back its 32% June rally — CEO Novogratz jumped the gun on a HPC deal and the market punished it. The setup actually improves from here: lower expectations into Q2 (EBITDA likely misses April guide), but August 31 is a real catalyst if ERCOT throws some unapproved capacity into Batch 0. McGregor interconnection details are the live wire.
"The current valuation provides a better setup ahead of a potential fourth-quarter announcement."
Q2 prints July 28 — 19 days away. McGregor bigger than expected? That's the swing factor. Helios Phase I is live (200MW to CoreWeave, 15-year lease), prediction markets launched, Tokenet investment announced. Narrative is coherent: energy + crypto infra → HPC pivot. Risk is the earnings miss is worse than the 1% PT cut implies.
UBS just cut estimates but didn't flinch on the Buy rating — which tells you this is about timing, not thesis. They trimmed Q2 EPS to $1.83 (vs Street $1.91) on a credit fee per million that came in 3% below bogey. Total credit volume also ~1% light. The stock's already down over 30% in six months, so the bad news is partially in the price. The question is whether the fee pressure is structural or cyclical.
Portfolio trading and block trading are "tracking well" per UBS, but not enough to offset softness in Eurobonds, EM, and US HY. Revenue forecast now pointing to -1.5% growth in Q2. Full-year 2026/27 EPS cut by ~5%.
"Key initiatives including portfolio trading and block trading are tracking well, but are not enough to offset weakness elsewhere."
THE NARRATIVE: The bull case rests on MKTX being a cheap option on secular electronification of fixed income (PEG of 0.29 is screaming cheap). The bear case — which Rothschild Redburn just endorsed with a downgrade to Neutral at $134 — is that market share gains are being offset by fee compression and competition. BofA upgraded to Neutral at $170, so the downgrade cycle might be pausing, but nobody's pounding the table. At $119, you're paying for optionality on a recovery in credit volumes, not for current momentum. Tough r/r until we see the fee per million trajectory stabilize.
CANTOR FIRES THE STARTER GUN ON VELO — initiate Overweight / $17 PT (24% upside from $13.75). The thesis is pure defense buildout: domestic manufacturing reshoring, supply chain de-risking, faster production timelines. VELO recapitalized after nearly hitting the wall, new management, now hitting the Russell 3000 + the Russell Microcap basket. A Mears Machine just ordered its fifth Sapphire XC printer (plus options for two more). Needham chimed in earlier with Buy. The narrative is clean.
“We expect stocks with growing aerospace and defense exposure to continue outperforming the market.” — Cantor
BUT. Not clean enough. Short-seller Morpheus Research went after CEO Dr. Arun Jeldi — fabricated background allegations, misrepresented business relationships. Stock got dinged. VELO’s trailing gross margin is NEGATIVE -11.33%. Analysts don’t see profitability this year. The bear case is that the pivot is real but the financials haven’t caught up, and the short-seller noise creates conviction drag.
Bottom line: Cantor is betting on the secular A&D wind at VELO’s back, not the Q/Q P&L. For PMs who buy the theme and can stomach the residual story risk, the r/r is interesting. For everyone else — wait for the next quarterly print to see if the gross margin line starts moving in the right direction.
Verdict: Bounce is real but this is still a high-beta bet on crypto and prediction volumes. Compass Point raised PT to $130 from $107, citing an 18% Q2 EBITDA beat driven by volumes and take rates. They also flagged prediction volumes sitting 57% above Q4 2025 levels despite a softer sports calendar, plus the 10% headcount cut announced June 16. Stock has already ripped 40% from the Q1 miss trough – risk/reward now hinges on whether the acceleration in prediction markets (and crypto) sustains through H2.
"Shares typically trade near the high end of this range when either crypto or prediction markets are accelerating."
Broader analyst positioning is constructive – Mizuho ($130), Piper Sandler ($135), and Truist ($100) all reiterated Buy ratings, though Barclays remains the outlier at $82. The key tension: 45x 2027E is not cheap, but the product cycle (Robinhood Chain, perpetual futures, custody support from BitGo) gives the narrative more legs than the 20x troughs. If prediction volumes keep growing and crypto stays bid, the multiple can expand again. If they roll over, the 50% drawdown playbook repeats.
STIFEL RAISED PT TO $260 FROM $240 but stuck with Hold. The bull case is almost entirely about the float income tailwind — they see FY27 client float income ~$90M ABOVE CONSENSUS, which is a ~30 BP MARGIN TAILWIND. That's the kind of rate-of-change dynamic that gets PMs interested in a name that usually just grinds.
BUT — Stifel is below consensus on PEO growth (5.5% vs street 6.1%), flagging blue-collar/gray-collar employment weakness and elevated healthcare costs. The Employer Services print at 5.5% is broadly in line. The HCM survey data about customers wanting to partner for AI deployment is a nice narrative hook but not a near-term catalyst.
"Stifel's pointing at a clear tactical edge on float income while keeping their PEO estimate 60bps below consensus — the offset makes the Hold make more sense than the PT raise alone."
THE MATH: Trades at 15.7x EV/FCF after SBC, in line with HCM comps at 16.5-18.3x. Dividend yield 2.8% with 27 consecutive years of hikes. Gross margins 48.5% — pristine business model, low churn, pricing power.
BULL CASE: Float income is structural, not cyclical. Fed stays elevated longer, ADP's cash float keeps printing above trend. The AI partnership angle gives the multiple room to expand toward comps. July 29 print could be a beat if Paychex's late June results are read-across.
BEAR CASE: PEO slowdown is real and could accelerate if healthcare costs keep rising. Labor market softening (NER Pulse showing weekly job adds dropping from 30.75k to 21k over four weeks) means pays-per-control deceleration. At 15.7x, you're paying for stability, not alpha — and the PT raise mostly just reflects the float one-off.
BOTTOM LINE: Float income is the story but that's FY27, not FY26. If you want payroll exposure and think the economy holds, ADP is fine. If you want torque, look elsewhere. The 7/29 print is the next catalyst — watch for guidance on float trajectory and PEO margin commentary.
HOLD AT $135, 17x EV/EBITDA. Jefferies resumes coverage with a Hold — not excited, not panicked. The Biocare acquisition just closed (June 25) and they model modest rev growth + slight op margin accretion, but EPS dilution near-term. Stock at $129 trades below that PT. No fireworks.
The bull case: reduced noise, unique growth drivers, healthy replacement cycle. The bear case: chemical/advanced materials segment and NASD are not yet fully de-risked. Neither side gets a knockout here — this is a wait-and-see setup.
"Bulls point to reduced noise, unique growth drivers and a healthy replacement cycle for the company. Bears cite concerns that the chemical and advanced materials segment and NASD have not been fully de-risked."
Other firms have taken more aggressive stances (Bernstein Outperform $155, Piper Neutral $150), but the only fresh paper is Jefferies' fence-sit. Not a catalyst for PMs to act.
MS slashes PT to $7.70 from $26 — but maintains Overweight. That's not a punchline, that's a bet on optionality. Stock at $5.78, near 52-week low of $5.32, down 57% YTD. The thesis hasn't changed on the end-state — it's all about when China's CAAC actually lets anyone fly paying passengers. Two companies with operational readiness have yet to commence service. That's the binding constraint, not readiness.
The constructive view rests on China's low-altitude policy support, the March 2025 passenger eVOL Operating Certificate, and EH's pilot city relationships. But absent real commercial revenue — and Q1 delivered only 4 units vs BofA's 14 estimate — there's no catalyst. MS's longer timeline drives the cut. BofA went to Underperform $5.40, JPM to Underweight. The cross is crowded on the short side, but the fundamental clock keeps ticking.
"The clearest catalyst would be genuine commercial revenue in China, which depends on the rollout of EHang's ground-crew training programs to build a pool of qualified operators." — Morgan Stanley
Wait for CAAC movement or a surprise order. Until then, this is a deep value call with binary regulatory risk and zero revenue visibility. Not a PM's typical sandbox.
Verdict: Small order, big narrative. Benchmark sticks to Buy / $6 (32% upside) after Odysight lands a ~$0.3M purchase order from Elbit Systems for the Israeli Ministry of Defense. That’s de minimis revenue for a $76M market cap burning cash on $1.03M LTM sales — but the signal is the pathway. Elbit acting on behalf of MoD + previous sole-source status = potential fleet-wide rollout. The real meat is the recurring monitoring revenue if the program scales.
"Benchmark stated the program may potentially evolve into a long-term recurring monitoring and analytics revenue project."
Context that matters: This builds on a CRADA with the US Navy (carrier arresting cables) and a GACI partnership for France’s aerospace/defense sector. The cash burn is real (current ratio 7.8 helps, but $1M rev isn’t funding ops), so every contract win is a proof-of-life. Benchmark already cut PT from $10 to $6 earlier — that revision is the honest baseline. This order alone doesn’t move the needle, but it keeps the defense thesis alive for PMs willing to play the optionality.
JPM finally pulling the trigger. Upgrade to Overweight from Neutral, PT raised to EUR87 from EUR73. The call is all about the AI moat — not just content, but owning mission-critical workflow platforms where AI amplifies rather than replaces. WKL trades at 9x 2027 EPS, a 40% discount to RELX and a 60% discount to US peers. That multiple compresses to 5x on 2030 numbers even assuming a slowdown in UpToDate. PEG ratio of 0.41 says the Street is pricing in zero AI optionality.
"AI moats are not just about proprietary content but rather ownership of mission-critical workflow platforms and systems of record, where AI enhances rather than replaces trusted data, embedded business processes and regulatory execution." — JPM
Goldman isn't a full bull yet — Neutral launch at EUR71, with 9% EPS CAGR through 2030, slightly below consensus. They see top-line acceleration after a soft Q1, but aren't ready to pay up for it. JPM's PT implies 12.9x 2027 P/E — still a 20% discount to Pearson. The risk/reward here is asymmetrically skewed if the AI workflow thesis gains traction.
BofA nudged ST PT to $48 from $46, stuck at Neutral. Not a scream — more of a "warm body, keep watching." The bull case hinges on durable operational improvement: automotive outgrowth from China platform wins, Japan ICE share gains, and data center sensor/electrical progress. Aero/def remains a reliable tailwind for modest margin expansion.
"The firm expects the company to emphasize durable operational improvement during its upcoming call"
YTD return +32.7% is already pricing in some of this. BofA flags macro headwinds and the measured pace of revenue/margin recovery as reasons not to get aggressive. Stock at $43.91 vs Street high $60 — plenty of runway if they execute, but the Neutral rating says they haven't proven it yet. Keep on radar for post-call momentum, not a pre-earnings bet.
Buy the pullback. KTOS is down 34% YTD — a pure multiple de-rate from 77x to 34x EV/EBITDA — while consensus FY26/27 EBITDA has been revised UP 10% since year-end. That’s the setup Jefferies is banking on: 110-120bps of margin expansion each year, driving EBITDA from $120M (FY25) to $263M (FY28). At 50x that, the $80 PT implies 50% upside. The narrative is about operating leverage finally showing up in a name that’s been a long-duration defense growth story.
Wedbush also chimed in with Outperform and $85, highlighting KTOS as a key supplier to the US defense base. Recent tangible catalysts: a 100K sq ft Oklahoma City expansion for jet drone production (currently ~165 units/year) and a $36M sole-source missile contract. EV/EBITDA compression this violent in a name with improving margins is the kind of r/r PMs should be checking.
“The underperformance has been driven by EV/EBITDA multiple de-rating from 77 times at year-end to 34 times… Consensus estimates for FY26 and FY27 EBITDA have been revised upward by 10% versus year-end 2025, with margins implying more than 100 basis points of expansion in both years.” — Jefferies
Stifel stays Buy at $18 (current $7.53) – the 310% YTD gain isn't a fluke, but the dilution fight is real. The DZYNE acquisition ($875.8mm, $200mm cash + 85mm shares) is the 14th since August, and organic growth is running 100% pro forma with $150mm in Q2 orders. The bull case: they're consolidating defense tech into a platform worth more than the sum, validated by Lockheed Martin picking Sentrycs for Sanctum. The bear case: 85mm new shares (13.8% of pro forma equity to Highlander) is a lot of overhang, even with a six-month lock-up.
"Investors are too distracted by share issuance related to the acquisitions." — Stifel
Needham and Lake Street both at $19 Buy post-deals, reinforcing the same thesis: scale, Lockheed tailwind, and a valuation that still works if organic momentum holds. The rate of change is extreme – 14 bolt-ons in <1 year – which makes the positioning call less about numbers and more about whether the market buys the platform narrative over the dilution math. Right now, it's buying.
SK Hynix (SKHY) The $26.5B US IPO (7x oversubscribed, ~$200B demand) is a landmark event that establishes SKHY as a second anchor for memory investing. 57% HBM market share and removal of price caps in LTAs signal confidence in sustained pricing power. The relative value trade against MU is now the most active memory debate — Hynix is winning on market share and pricing flexibility.
Hearing... from ICML: Meta has already developed an internal model at roughly the Mythos 5 level, and deployment is imminent within months. If true, that would put Meta firmly in the frontier-labs race and debunk the "excess compute" narrative — compute demand stays elevated.
Word is... Anthropic's successful Claude training on Google TPUs is accelerating TPU adoption outside Google. Several unnamed frontier labs are now evaluating TPU clusters as a viable NVIDIA alternative — a structural shift that could pressure GPU pricing over the medium term.
Channel checks suggest... Starbucks' in-house AI tools replacing IBM software is not isolated. Multiple large enterprises are quietly building custom AI replacements for legacy vendor applications. The disintermediation risk is real but not yet reflected in enterprise software multiples.
Hearing... OpenAI's internal data shows agentic token usage increased 22x over six months. That's a massive demand elasticity signal — Jevons paradox in action. The GPT-5.6 launch with persistent agent layers (ChatGPT Work) will compound this further. Inference infrastructure demand is being structurally underpriced by sell-side models.
Word is... SK Hynix's removal of price caps in LTAs caught some large CSPs off guard. One hyperscaler procurement team is reportedly renegotiating terms to avoid unlimited upside in contract pricing. This creates a wedge between Hynix and Micron — MU's capped LTAs may be more favorable for customers, but Hynix captures more pricing upside.
Rumor from the supply chain... Coherent's laser quality issue is not isolated to one part number. Multiple tier-2 optical module makers are reportedly struggling with yield on Coherent's 400mw-class lasers, while Lumentum's equivalent parts are shipping at full volume to multiple customers. If true, Coherent could lose significant share in the 1.6T ramp.